 CAMBRIDGE, Mass., Aug. 05, 2020 GLOBE NEWSWIRE -- Fulcrum Therapeutics, Inc. Nasdaq: FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2020 financial results will be released on Tuesday, August 11, 2020 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments. Dial-in Number U.S.Canada Dial-in Number: 800-527-6973 International Dial-in Number: 470-495-9162 Conference ID: 9625789Replay Dial-in Number: 855-859-2056 Replay International Dial-in Number: 404-537-3406 Conference ID: 9625789An audio webcast will be accessible through the Investor Relations section of the companys website Following the live webcast, an archived replay will also be available.About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrums proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy FSHD and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates a regulatory filing in the second half of 2020 with FTX-6058 for the treatment of sickle cell disease.Please visit Christi Waarich Director, Investor Relations and Corporate Communications 617-651-8664 